Germ Cell Tumor Clinical Trial
Official title:
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
The goal of this clinical trial is to assess the efficacy of thromboprophylaxis in preventing venous thromboembolic events (VTE) in good and intermediate prognosis patients with metastatic germ cell cancer (GCT) undergoing first-line cisplatin-based chemotherapy with risk factors for developing a thromboembolic event . The high-risk patients will be randomized between two treatments arm (receiving a thromboprophylaxis in the experimental arm, or no thromboprophylaxis in the control arm). The low-risk patients will be observed without any thromboprophylaxis. Patients will participate in the study for 14-17 weeks depending on the planned number of cycles of chemotherapy. Researchers will compare an experimental arm with thromboprophylaxis and a control arm without thromboprophylaxis to detect an absolute decrease of 12% of the proportion of patients having experienced a VTE, from 21% (high risk patients, control arm) to 9% (high risk patients, experimental arm).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06133543 -
Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
|
N/A | |
| Terminated |
NCT00369291 -
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
|
Phase 1 | |
| Terminated |
NCT00198172 -
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
|
Phase 2 | |
| Completed |
NCT03194906 -
Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
|
Phase 2 | |
| Completed |
NCT01466231 -
Everolimus in Refractory Testicular Germ Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT04791228 -
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03418844 -
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
|
N/A | |
| Recruiting |
NCT05889585 -
Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated With High-dose Chemotherapy and Autologous Stem Cell Transplant
|
||
| Recruiting |
NCT05394675 -
A Study of DS-9606a in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT03067181 -
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
|
Phase 3 | |
| Withdrawn |
NCT03960151 -
Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy
|
Phase 2 | |
| Active, not recruiting |
NCT03158064 -
Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
|
Phase 2 | |
| Completed |
NCT03950830 -
Disulfiram and Cisplatin in Refractory TGCTs.
|
Phase 2 | |
| Recruiting |
NCT00898755 -
Collecting and Storing Tissue From Young Patients With Cancer
|
||
| Recruiting |
NCT04804007 -
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
|
Phase 2 | |
| Terminated |
NCT02988843 -
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
|
Phase 2 | |
| Recruiting |
NCT05259605 -
Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
|
||
| Active, not recruiting |
NCT03638167 -
EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
|
Phase 1 | |
| Recruiting |
NCT04308330 -
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
|
Phase 1 | |
| Recruiting |
NCT06418789 -
High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors
|
Phase 2 |